Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Lexington, Kentucky Clinical Trials

A listing of Lexington, Kentucky clinical trials actively recruiting patient volunteers.

RESULTS

Found (27) clinical trials

Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism

This study is being conducted to characterize the effects of twice daily administration of rhPTH(1-84) on the way the body handles rhPTH(1-84) as well as its actions and safety and tolerability over the course of 24 hours as compared with the current once daily dosing regimen of marketed rhPTH(1-84) (marketed ...

Phase

1.58 miles

Learn More »

Reinforcing Effects of Cocaine During Phendimetrazine Maintenance

This study will determine the initial efficacy of phendimetrazine as a pharmacotherapy for cocaine dependence. A rigorous, inpatient human laboratory study will be conducted in which the subjective, physiological and reinforcing effects of cocaine are evaluated during maintenance on placebo and phendimetrazine.

Phase

1.58 miles

Learn More »

Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors

This is a first in man study of BXQ-350, a novel anti-neoplastic therapeutic agent composed of two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. When both the components are assembled together forming stable SapC-DOPS nanovesicles (clinical formulation ...

Phase

1.61 miles

Learn More »

Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian Fallopian Tube Or Peritoneal Cancer

Pegylated liposomal doxorubicin (PLD; e.g., Doxil®, Lipodox™) will be administered intravenously on Day 1 and EGEN-001 will be administered intraperitoneally on Day 1, 8, 15, and 22 of a 28-day cycle to determine: - The maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of EGEN-001 when administered in combination ...

Phase

1.61 miles

Learn More »

A Study to Evaluate the Safety Tolerability and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease

The purpose of the study is to assess the safety, tolerability, and pharmacokinetics of single, ascending doses of ABBV-951 administered as a subcutaneous bolus infusion followed by a continuous subcutaneous infusion in subjects with Parkinson's disease.

Phase

1.61 miles

Learn More »

Adavosertib External Beam Radiation Therapy and Cisplatin in Treating Patients With Cervical Vaginal or Uterine Cancer

PRIMARY OBJECTIVES: I. To determine the recommended phase II dose (RP2D) and safety profile of adavosertib (AZD1775) in combination with radiotherapy and concurrent cisplatin in patients with gynecological cancers. SECONDARY OBJECTIVES: I. To determine the acute and late toxicity of AZD1775 when administered to patients with gynecological cancer in combination ...

Phase

1.61 miles

Learn More »

MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed Refractory or Newly-Diagnosed Acute Myeloid Leukemia

PRIMARY OBJECTIVES: I. To evaluate the toxicities of MDM2 inhibitor AMG-232 (AMG-232) in combination with decitabine (20 mg/m^2 for 10 days), and to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of AMG-232 in combination with a standard dose of decitabine. SECONDARY OBJECTIVES: I. To evaluate the pharmacokinetic ...

Phase

1.61 miles

Learn More »

Biological Effects of Agent on PAR-4 Levels With Resected Solid Tumors

Hydroxychloroquine will be administered on an outpatient basis within 12 weeks after primary surgery followed by adjuvant chemotherapy /or radiation therapy (if needed). Hydroxychloroquine will be administered orally at a dose of 400 mg daily for 90 days. Subjects will receive HCQ every day.

Phase

1.61 miles

Learn More »

Magnesium And Verapamil After Recanalization in Ischemia of the Cerebrum: a Clinical and Translational Study.

Participants will be recruited from patients evaluated at University of Kentucky Chandler Hospital for acute ischemic stroke. Participants with impaired capacity may be included, as the pathology to be studied (stroke) may impair their capacity. Initial contact will be made by the sub-investigators approved to obtain consent; all sub-investigators are ...

Phase

1.61 miles

Learn More »

Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure

PRIMARY OBJECTIVES: I. To assess safety, tolerability, and identify the maximum tolerated dose (MTD) of entinostat given in combination with MK-3475 (pembrolizumab). SECONDARY OBJECTIVES: I. To obtain a preliminary estimate of efficacy of entinostat in combination with MK-3475 (pembrolizumab). TERTIARY OBJECTIVES: I. To assess the dynamic quantitative change in measurable ...

Phase

1.61 miles

Learn More »